Table 1.
Demographics, clinical features, and medication use in GBA-PD and IPD
| GBA-PD (n = 34) | IPD (n = 60) | p value | |
|---|---|---|---|
| Women, n (%) | 17 (50.0) | 28 (46.7) | 0.76 |
| Age of onset, years | 57.5 (48, 65) | 59 (51, 66) | 0.44 |
| Time to first evaluation, years | 2.4 (1.0, 5.7) | 2.0 (1.4, 5.0) | 0.90 |
| Duration of disease, years | 9.3 (5.9, 15.1) | 8.4 (7.0, 12.5) | 0.99 |
| Duration of clinical follow-up, years | 5.1 (3.1, 9.2) | 5.4 (3.0, 8.5) | 0.83 |
| Education, n (%) | 0.28 | ||
| High School | 4 (11.8) | 2 (1.8) | |
| Undergraduate | 13 (38.2) | 27 (48.2) | |
| Graduate | 17 (50.0) | 27 (48.2) (n = 56) | |
| UPDRS III at last visit | 20.5 (15, 30) | 16 (13, 26.5) (n = 52) | 0.26 |
| Levodopa equivalents at last visit, mg | 715.8 (400, 1,000) | 598.5 (432.5, 887.5) | 0.22 |
| Dopamine agonist at last visit, n (%) | 12 (35.3) | 26 (43.3) | 0.29 |
| Mentation consistently >1, n (%) | 9 (26.5) | 7 (11.7) | 0.07 |
| Cholinesterase inhibitor >6 months, n (%) | 14 (41.2) | 9 (15.0) | 0.005 |
| Hallucinations >1, n (%) | 17(50.0) | 18 (30.0) | 0.054 |
| Hallucinations >1 for 6 months, n (%) | 9 (26.5) | 4 (6.7) | 0.01 |
| Antipsychotic >6 months, n (%) | 6 (17.7) | 7 (11.7) | 0.54 |
Continuous variables are reported as medians with interquartile ranges. GBA-PD Parkinson disease with heterozygous GBA mutations, IPD idiopathic Parkinson disease, UPDRS Unified Parkinson’s Disease Rating Scale